scispace - formally typeset
G

Guido Kroemer

Researcher at Institut Gustave Roussy

Publications -  1546
Citations -  294816

Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.

Papers
More filters
Journal ArticleDOI

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Melody Smith, +8 more
- 11 Oct 2018 - 
TL;DR: Recent preclinical and clinical advances in the development of TLR agonists for cancer therapy are summarized.
Journal ArticleDOI

Mechanisms of apoptotic phosphatidylserine exposure

Guillermo Mariño, +1 more
- 27 Aug 2013 - 
TL;DR: In a recent paper in Science, Nagata and coworkers reveal that the scramblases Xkr8 and its C. elegans ortholog, CED-8, are activated by caspase cleavage in apoptotic cells.
Journal ArticleDOI

Autophagy in acute brain injury

Lorenzo Galluzzi, +3 more
- 01 Aug 2016 - 
TL;DR: The context-specific impact of autophagy on non-infectious acute brain injury is dissected, emphasizing the possible therapeutic application of pharmacological activators and inhibitors of this catabolic process for neuroprotection.
Journal ArticleDOI

Autophagic removal of micronuclei.

Santiago Rello-Varona, +11 more
- 01 Jan 2012 - 
TL;DR: Results indicate that micron nuclei can be subjected to autophagic degradation and it can be speculated that removal of micronuclei may contribute to the genome-stabilizing effects of autophagy.
Journal Article

Prion diseases are efficiently transmitted by blood transfusion in sheep. Commentary

Laurence Zitvogel, +11 more
- 01 Jan 2008 - 
TL;DR: In this paper, the authors used sheep as a model for studying transmission of variant Creutzfeld-Jakob disease by blood products in humans and found high transmission rates and relatively short and consistent incubation periods in clinically positive recipients.